Fludarabine, Bortezomib, Myocet® and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma

British Journal of Haematology

Volumn 148, Issue 5, 2010, Pages 810-812

  Orciuolo, Enrico ^a   Buda, Gabriele ^a   Pelosini, Matteo ^a   Petrini, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Bortezomib; Fludarabine; Liposomal doxorubicin; Mantle cell lymphoma; Rituximab

Indexed keywords

ACICLOVIR; BORTEZOMIB; COTRIMOXAZOLE; DOXORUBICIN; ERYTHROPOIETIN; FLUCONAZOLE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RECURRENCE; CANCER RELAPSE; CARDIOTOXICITY; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFECTION; INFECTION PREVENTION; LETTER; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PYRAZINES; VIDARABINE;

EID: 76449114029     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07998.x     Document Type: Letter

References (10)

1. Barr, P.M., Fu, P., Lazarus, H.M., Horvath, N., Gerson, S.L., Koc, O.N., Bahlis, N.J., Snell, M.R., Dowlati, A. Cooper, B.W. (2009) Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. British Journal of Haematology, 147, 89 96.
2. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579 586.
3. Ewer, M.S., Martin, F.J., Henderson, C., Shapiro, C.L., Benjamin, R.S. Gabizon, A.A. (2004) Cardiac safety of liposomal anthracyclines. Seminars in Oncoogy, 31 (6 Suppl. 13 161 181.
4. Fayad, L., Thomas, D. Romaguera, J. (2007) Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clinical Lymphoma and Myeloma, 8 (Suppl. 2 S57 S62.
5. Fisher, R.I., Bernstein, S.H., Kahl, B.S., Djulbegovic, B., Robertson, M.J., de Vos, S., Epner, E., Krishnan, A., Leonard, J.P., Lonial, S., Stadtmauer, E.A., O'Connor, O.A., Shi, H., Boral, A.L. Goy, A. (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology, 24, 4867 4874.
6. Forstpointner, R., Dreyling, M., Repp, R., Hermann, S., Hanel, A., Metzner, B., Pott, C., Hartmann, F., Rothmann, F., Rohrberg, R., Bock, H.P., Wandt, H., Unterhalt, M. Hiddemann, W. (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 104, 3064 3071.
7. Lenz, G., Dreyling, M., Hoster, E., Wormann, B., Duhrsen, U., Metzner, B., Eimermacher, H., Neubauer, A., Wandt, H., Steinhauer, H., Martin, S., Heidemann, E., Aldaoud, A., Parwaresch, R., Hasford, J., Unterhalt, M. Hiddemann, W. (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Journal of Clinical Oncology, 23, 1984 1992.
8. Orciuolo, E., Buda, G., Cecconi, N., Galimberti, S., Versari, D., Cervetti, G., Salvetti, A. Petrini, M. (2007) Unexpected cardiotoxicity in haematological bortezomib treated patients. British Journal of Haematology, 138, 396 397.
9. Orlowski, R.Z., Nagler, A., Sonneveld, P., Blade, J., Hajek, R., Spencer, A., San Miguel, J., Robak, T., Dmoszynska, A., Horvath, N., Spicka, I., Sutherland, H.J., Suvorov, A.N., Zhuang, S.H., Parekh, T., Xiu, L., Yuan, Z., Rackoff, W. Harousseau, J.L. (2007) Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. Journal of Clinical Oncology, 25, 3892 3901.
10. Sonneveld, P., Hajek, R., Nagler, A., Spencer, A., Blade, J., Robak, T., Zhuang, S.H., Harousseau, J.L. Orlowski, R.Z. (2008) Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/ lenalidomide therapy. Cancer, 112, 1529 1537.